Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: July 07, 2026
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.
Journal: Journal of medical virology
Published: October 12, 2024
GS143, an inhibitor of E3 ligase β-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFκB.
Journal: PLoS pathogens
Published: August 09, 2024
Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses.
Journal: Emerging microbes & infections
Published: April 30, 2024
The Association of Serotonin Toxicity with Combination Linezolid-Serotonergic Agent Therapy: A Systematic Review and Meta-Analysis.
Journal: Pharmacy (Basel, Switzerland)
Published: September 14, 2023
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.
Journal: JHEP reports : innovation in hepatology
Published: August 17, 2023
Successful Treatment of Cutibacterium acnes Prosthetic Joint Infection With Single-Stage Exchange and Oral Antibiotics.
Journal: Open forum infectious diseases
Published: June 05, 2023
Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin-Preclinical and Clinical Evidence.
Journal: Pharmaceutics
Published: November 03, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Journal: Annals of internal medicine
Published: August 08, 2022
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection.
Journal: Journal of addictive diseases
Published: August 03, 2022
Last Updated: 09/26/2026